Seaport Therapeutics Finds Frequent Assessments Boost Placebo Response in Anxiety Trials
Event summary
- Seaport Therapeutics presented a meta-analysis at the ISCTM Conference on February 18-20, 2026, showing frequent clinician-administered assessments (CAAs) increase placebo response in generalized anxiety disorder (GAD) trials.
- The analysis examined 22 industry-sponsored Phase 2-4 GAD trials over the past 20 years, all using the Hamilton Anxiety Rating Scale (HAM-A) as the primary endpoint.
- Other factors like baseline HAM-A score, number of trial sites, and patient number showed no strong correlation with placebo response.
- Findings align with Seaport’s earlier meta-analysis in major depressive disorder (MDD) trials, reinforcing the impact of CAAs on placebo response.
The big picture
Seaport Therapeutics’ meta-analysis underscores the persistent challenges in CNS drug development, where high placebo response can obscure efficacy. The findings align with broader industry trends highlighting the need for optimized clinical trial designs to improve success rates in neuropsychiatric drug development. Over 90% of neuropsychiatry product candidates fail, according to the Biotechnology Innovation Organization, making trial design a critical factor in overcoming this barrier.
What we're watching
- Trial Design Optimization
- How Seaport will apply these insights to future clinical trial designs to mitigate placebo response in neuropsychiatric trials.
- Industry Adoption
- Whether other biotech and pharmaceutical companies will adopt similar trial design adjustments based on Seaport’s findings.
- Regulatory Impact
- The pace at which regulatory bodies may incorporate these findings into guidelines for neuropsychiatric drug development.
Related topics